IDEXX LABORATORIES INC /DE — Director's Dealing 2016

Nov 10, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2016-11-09

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-11-09	Common Stock	M	40000	$26.6550	Acquired	1027855	Direct
2016-11-09	Common Stock	S	5767	$106.2535	Disposed	1022088	Direct
2016-11-09	Common Stock	S	6433	$107.4776	Disposed	1015655	Direct
2016-11-09	Common Stock	S	27800	$108.2741	Disposed	987855	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-11-09	Non-Qualified Stock Option (right-to-buy)	$26.6550	M	40000	Disposed	2017-02-13	Common Stock (40000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	98000	Indirect

Footnotes

F1: Includes 65 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2016.

F2: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $105.81 to a high of $106.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sales price of the shares sold ranging from a low of $106.87 to a high of $107.835 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: Represents the weighted average sales price of the shares sold ranging from a low of $107.90 to a high of $108.81 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: Grant of option to buy 78,125 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 16,000 shares each beginning on February 14, 2011 and as to the remaining 14,125 shares on February 14, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Not applicable.